<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00657423</url>
  </required_header>
  <id_info>
    <org_study_id>XJ-EnXS0802</org_study_id>
    <nct_id>NCT00657423</nct_id>
  </id_info>
  <brief_title>Impact of Endostar Combined With Chemotherapy on the Angiogenesis of Advanced Non-small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>Study of Endostar Combined With Docetaxel and Cisplatin on the Angiogenesis of Advanced Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yantai Medgenn Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the impact of endostar combined with docetaxel and cisplatin on the angiogenesis of
      non-small cell lung cancer, patients will be randomly assigned to the group one (endostar
      combined with docetaxel and cisplatin) and group two (docetaxel and cisplatin).

        -  The serum concentrations of Endostatin,VEGF and bFGF are determined.

        -  Blood circulating endothelial cells (CECs) and circulating hematopoietic progenitor
           cells (CPCs) will be measured by flow cytometer.

        -  Statistical analysis will be applied to study the relationship between the levels of
           Endostatin, VEGF, bFGF, CECs and CPCs and the clinical outcomes such as objective
           response rate(ORT), time to progression (TTP), mean survival time(MST), toxicity and
           quality of life (QOL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To study the impact of endostar combined with docetaxel and cisplatin on the angiogenesis of
      non-small cell lung cancer,patients will be randomly assigned to the experimental
      group(endostar combined with docetaxel and cisplatin) and the control group (docetaxel and
      cisplatin).

        -  the serum concentrations of Endostatin,VEGF and bFGF are determined.

        -  Blood circulating endothelial cells (CECs) and circulating hematopoietic progenitor
           cells (CPCs) will be measured by flow cytometer.

        -  the clinical parameters such as objective response rate (ORT),time to progression(TTP)
           and mean survival time(MST) will be collected according to the WHO criteria.

        -  the toxicity will be recorded according to the NCI-CTC v3.0.

        -  the Quality of life was self-assessed using the European Organisation for Research and
           Treatment of Cancer (EORTC) QLQ C-30 questionnaire.

        -  Statistical analysis will be applied to study the relationship between the levels of
           Endostatin,VEGF,bFGF,CECs and CPCs and the clinical outcomes such as ORT, TTP, MST,
           toxicity and QOL.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2008</start_date>
  <completion_date type="Anticipated">April 2009</completion_date>
  <primary_completion_date type="Anticipated">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mean survival time</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Lung Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treated by endostar combined with docetaxel and cisplatin</intervention_name>
    <description>recombinant human endostatin given intravenously,7.5mg/㎡,d1-14,2cycles. docetaxel given intravenously,75mg/㎡,d1,2cycles. cisplatin given intravenously,75mg/㎡,d1,2cycles.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Endostar</other_name>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treated by docetaxel and cisplatin</intervention_name>
    <description>docetaxel given intravenously,75mg/㎡,d1,2cycles. cisplatin given intravenously,75mg/㎡,d1,2cycles.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of advanced or metastatic NSCLC (confirmed histologically, with a
             tumor that was measurable by clinical and/or radiologic examination.

          -  Have an Eastern Cooperative Oncology Group performance status 0 to 2.

          -  Adequate renal, cardiac, hepatic, and hematologic function as indicated by the
             following parameters: absolute neutrophil count 2 x the ninth power of ten/L,
             thrombocytes 100 x the ninth power of ten/L, hemoglobin 10 g/dL, total bilirubin 1.25x
             the upper limit of normal range (ULN), ALT and AST 1.5x ULN, alkaline phosphatase 5x
             ULN, creatinine 1.15x ULN.

        Exclusion Criteria:

          -  Known brain metastases or secondary neoplasia.

          -  Myocardial insufficiency or myocardial infarction within the preceding 6 months.

          -  Severe renal or hepatic insufficiency.

          -  Pre-existing motor or sensor neurotoxicity WHO grade 2.

          -  Severe psychologic disease.

          -  Active infection, or other condition that could compromise protocol compliance.

          -  Simultaneous administration of other antineoplastic medications.

          -  Clinically significant hemoptysis.

          -  Pregnancy and/or lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Changgui Wu, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. Resp. Diseases, Xijing Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shengqing Li, MD, PHD</last_name>
    <phone>086-029-84771132</phone>
    <email>shengqingli@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dept. Resp. Diseases, Xijing Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shengqing Li, MD. PHD.</last_name>
      <phone>086-029-84771132</phone>
      <email>shengqingli@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2008</study_first_submitted>
  <study_first_submitted_qc>April 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2008</study_first_posted>
  <last_update_submitted>September 15, 2010</last_update_submitted>
  <last_update_submitted_qc>September 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Shengqing Li</name_title>
    <organization>Dept.of Respiratory Diseases, Xijing Hospital</organization>
  </responsible_party>
  <keyword>Lung Neoplasms</keyword>
  <keyword>Endostatins</keyword>
  <keyword>Vascular Endothelial Growth Factors</keyword>
  <keyword>Fibroblast Growth Factors</keyword>
  <keyword>Survival Rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Endostatins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

